CBD SCIENCE Trademark

Trademark Overview

On Tuesday, March 5, 2019, a trademark application was filed for CBD SCIENCE with the United States Patent and Trademark Office. The USPTO has given the CBD SCIENCE trademark a serial number of 88326351. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Monday, September 11, 2023. This trademark is owned by Boston Research & Development, LLC. The CBD SCIENCE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of pain, disease, illness, and injury; pharmaceutical preparations for the treatment of neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, and metabolic disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for therapeutic purposes in the treatment of pain, disease, illness, and injury; pharmaceutical preparations for the treatment of mental illness; dietary supplements; all of the foregoing containing CBD solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis
cbd science

General Information

Serial Number88326351
Word MarkCBD SCIENCE
Filing DateTuesday, March 5, 2019
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateMonday, September 11, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of pain, disease, illness, and injury; pharmaceutical preparations for the treatment of neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, and metabolic disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for therapeutic purposes in the treatment of pain, disease, illness, and injury; pharmaceutical preparations for the treatment of mental illness; dietary supplements; all of the foregoing containing CBD solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 22, 2019
Primary Code005
First Use Anywhere DateTuesday, September 18, 2018
First Use In Commerce DateTuesday, September 18, 2018

Trademark Owner History

Party NameBoston Research & Development, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNorwood, MA 02062

Trademark Events

Event DateEvent Description
Tuesday, September 26, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Tuesday, September 26, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Monday, September 11, 2023ABANDONMENT - AFTER EX PARTE APPEAL
Monday, September 11, 2023EXPARTE APPEAL TERMINATED
Tuesday, August 1, 2023EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
Friday, May 19, 2023NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Friday, May 19, 2023ACTION DENYING REQ FOR RECON E-MAILED
Friday, May 19, 2023ACTION CONTINUING FINAL - COMPLETED
Thursday, November 3, 2022AMENDMENT TO USE PROCESSING COMPLETE
Tuesday, October 12, 2021USE AMENDMENT FILED
Thursday, September 29, 2022DIVISIONAL PROCESSING COMPLETE
Tuesday, October 12, 2021DIVISIONAL REQUEST RECEIVED
Wednesday, September 28, 2022ASSIGNED TO LIE
Wednesday, August 3, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, October 12, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, October 12, 2021TEAS AMENDMENT OF USE RECEIVED
Tuesday, October 12, 2021JURISDICTION RESTORED TO EXAMINING ATTORNEY
Tuesday, October 12, 2021EX PARTE APPEAL-INSTITUTED
Tuesday, October 12, 2021EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, October 12, 2021TEAS REQUEST TO DIVIDE RECEIVED
Friday, April 9, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, April 9, 2021FINAL REFUSAL E-MAILED
Friday, April 9, 2021FINAL REFUSAL WRITTEN
Thursday, March 18, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 18, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 17, 2021ASSIGNED TO LIE
Tuesday, December 15, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, June 15, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, June 15, 2020NON-FINAL ACTION E-MAILED
Monday, June 15, 2020NON-FINAL ACTION WRITTEN
Thursday, May 21, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 21, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 21, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 21, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 21, 2019NON-FINAL ACTION E-MAILED
Thursday, November 21, 2019NON-FINAL ACTION WRITTEN
Thursday, November 14, 2019ASSIGNED TO EXAMINER
Sunday, March 31, 2019ASSIGNED TO EXAMINER
Friday, March 22, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 8, 2019NEW APPLICATION ENTERED

Related Keywords

science pharmaceutical preparations pain treatment injury illness disease cancer derived containing